KR20060054187A - 항암제로서의 헤테로아릴-접합된 피리미디닐 화합물 - Google Patents

항암제로서의 헤테로아릴-접합된 피리미디닐 화합물 Download PDF

Info

Publication number
KR20060054187A
KR20060054187A KR1020057022768A KR20057022768A KR20060054187A KR 20060054187 A KR20060054187 A KR 20060054187A KR 1020057022768 A KR1020057022768 A KR 1020057022768A KR 20057022768 A KR20057022768 A KR 20057022768A KR 20060054187 A KR20060054187 A KR 20060054187A
Authority
KR
South Korea
Prior art keywords
compound
substituted
hydrogen
aryl
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020057022768A
Other languages
English (en)
Korean (ko)
Inventor
웨이보 왕
리아나 엠. 래그니톤
리안 엔. 콘스탄틴
매튜 티. 버거
Original Assignee
카이론 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 카이론 코포레이션 filed Critical 카이론 코포레이션
Publication of KR20060054187A publication Critical patent/KR20060054187A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020057022768A 2003-05-30 2004-05-27 항암제로서의 헤테로아릴-접합된 피리미디닐 화합물 Ceased KR20060054187A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47468403P 2003-05-30 2003-05-30
US60/474,684 2003-05-30

Publications (1)

Publication Number Publication Date
KR20060054187A true KR20060054187A (ko) 2006-05-22

Family

ID=33551504

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020057022768A Ceased KR20060054187A (ko) 2003-05-30 2004-05-27 항암제로서의 헤테로아릴-접합된 피리미디닐 화합물

Country Status (10)

Country Link
US (2) US7345046B2 (cg-RX-API-DMAC7.html)
EP (1) EP1636238A1 (cg-RX-API-DMAC7.html)
JP (1) JP2007500237A (cg-RX-API-DMAC7.html)
KR (1) KR20060054187A (cg-RX-API-DMAC7.html)
CN (1) CN100418971C (cg-RX-API-DMAC7.html)
AU (1) AU2004247650A1 (cg-RX-API-DMAC7.html)
CA (1) CA2526217A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA05012706A (cg-RX-API-DMAC7.html)
TW (1) TW200505454A (cg-RX-API-DMAC7.html)
WO (1) WO2004111058A1 (cg-RX-API-DMAC7.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR050920A1 (es) * 2003-03-07 2006-12-06 Astrazeneca Ab Enantiomeros de heterociclos fusionados seleccionados y usos de los mismos
PT1601673E (pt) * 2003-03-07 2009-07-29 Astrazeneca Ab Heterociclos fundidos e suas utilizações
US7572914B2 (en) * 2003-12-19 2009-08-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
ATE419249T1 (de) * 2004-04-06 2009-01-15 Novartis Vaccines & Diagnostic Inhibitoren von mitotischem kinesin
WO2005105788A1 (en) * 2004-04-23 2005-11-10 Takeda San Diego, Inc. Indole derivatives and use thereof as kinase inhibitors
US20070287703A1 (en) * 2004-07-22 2007-12-13 Astrazeneca Ab Fused Pyrimidones Useful in the Treatment and the Prevention of Cancer
CN101027309B (zh) * 2004-08-18 2010-10-27 阿斯利康(瑞典)有限公司 所选择的稠合嘧啶酮的对映体和在治疗和预防癌症中的用途
KR20070046175A (ko) * 2004-08-18 2007-05-02 아스트라제네카 아베 선택된 융합 복소환 및 이의 용도
WO2006023931A2 (en) * 2004-08-18 2006-03-02 Takeda San Diego, Inc. Kinase inhibitors
EP1812439B2 (en) 2004-10-15 2017-12-06 Takeda Pharmaceutical Company Limited Kinase inhibitors
US7608643B2 (en) 2005-03-09 2009-10-27 Schering Corporation Compounds for inhibiting KSP kinesin activity
AR053158A1 (es) * 2005-03-09 2007-04-25 Schering Corp Compuestos para inhibir la actividad de quinesina de ksp
EP1871776A2 (en) * 2005-03-09 2008-01-02 Schering Corporation Fused thieno[2,3-b]pyridine and thiazolo[5,4-b]pyridine compounds for inhibiting ksp kinesin activity
DE102005011822A1 (de) * 2005-03-15 2006-09-21 Merck Patent Gmbh Phthalazinone
AU2011205048B2 (en) * 2005-05-13 2013-05-02 Virochem Pharma Inc. Compounds and methods for the treatment or prevention of flavivirus infections
JP5030947B2 (ja) 2005-05-13 2012-09-19 ヴァイロケム・ファーマ・インコーポレーテッド フラビウイルス感染の治療及び予防のための化合物及び方法
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
JP2010505962A (ja) 2006-10-09 2010-02-25 武田薬品工業株式会社 キナーゼ阻害剤
ES2373867T3 (es) * 2007-03-02 2012-02-09 The University Of Wollongong Composiciones y procedimientos para el suministro de agentes anticancerosos.
WO2008147852A1 (en) * 2007-05-22 2008-12-04 Taigen Biotechnology Co., Ltd. Kinesin inhibitors
CN101801937A (zh) 2007-06-22 2010-08-11 艾科尔公司 喹唑啉酮化合物及其使用方法
AR069869A1 (es) * 2007-12-21 2010-02-24 Exelixis Inc Derivados de benzofuro[3,2-d]pirimidinas inhibidores de proteinquinasas,composiciones farmaceuticas que los comprenden y usos de los mismos en el tratamiento del cancer.
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3964507A1 (en) 2013-10-04 2022-03-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN106456628A (zh) 2014-03-19 2017-02-22 无限药品股份有限公司 用于治疗PI3K‑γ介导的障碍的杂环化合物
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3240541A4 (en) * 2014-12-29 2018-07-25 New Mexico Tech Research Foundation Synthetic rigidin analogues as anti-cancer agents, salts, solvates and prodrugs thereof, and method of producing same
CN114230571B (zh) 2015-09-14 2025-07-08 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
WO2017112777A1 (en) 2015-12-22 2017-06-29 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
KR102736865B1 (ko) 2017-06-21 2024-12-03 샤이 테라퓨틱스 엘엘씨 암, 염증성 질환, 신경발달질환 및 섬유증 질환의 치료를 위하여 Ras 수퍼패밀리와 상호작용하는 화합물
JP7407461B2 (ja) 2018-12-19 2024-01-04 シャイ・セラピューティクス・エルエルシー がん、炎症性疾患、ras病、及び線維性疾患の処置のためのrasスーパーファミリーと相互作用する化合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0720969B2 (ja) * 1988-03-02 1995-03-08 吉富製薬株式会社 3,4―ジヒドロチエノ〔2,3―d〕ピリミジン化合物およびその医薬用途
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
NZ526622A (en) 2000-12-11 2006-07-28 Amgen Sf Llc CXCR3 antagonists
CA2465491A1 (en) 2001-11-07 2003-05-15 Merck & Co., Inc. Mitotic kinesin inhibitors
CA2467916A1 (en) 2001-12-06 2003-06-19 Merck & Co., Inc. Mitotic kinesin inhibitors
WO2003050122A2 (en) 2001-12-06 2003-06-19 Merck & Co., Inc. Mitotic kinesin inhibitors
JP4467979B2 (ja) 2001-12-06 2010-05-26 メルク・シャープ・エンド・ドーム・コーポレイション 有糸分裂キネシン阻害剤
ATE372341T1 (de) 2001-12-06 2007-09-15 Merck & Co Inc Inhibitoren von mitotischem kinesin
WO2003103575A2 (en) 2002-05-23 2003-12-18 Cytokinetics, Inc. Compounds, compositions, and methods
EP1517904A4 (en) 2002-05-23 2007-02-21 Merck & Co Inc INHIBITORS OF MITOTIC KINESINE
WO2004034972A2 (en) 2002-09-30 2004-04-29 Cytokinetics, Inc. Compounds, compositions, and methods

Also Published As

Publication number Publication date
EP1636238A1 (en) 2006-03-22
CN100418971C (zh) 2008-09-17
TW200505454A (en) 2005-02-16
WO2004111058A1 (en) 2004-12-23
MXPA05012706A (es) 2006-02-08
CA2526217A1 (en) 2004-12-23
JP2007500237A (ja) 2007-01-11
US20050065169A1 (en) 2005-03-24
US7345046B2 (en) 2008-03-18
US20080069817A1 (en) 2008-03-20
AU2004247650A1 (en) 2004-12-23
CN1798749A (zh) 2006-07-05

Similar Documents

Publication Publication Date Title
US7345046B2 (en) Heteroaryl-fused pyrimidinyl compounds as anticancer agents
EP1689724B1 (en) Quinazolinone compounds as anticancer agents
EP1636225B1 (en) Pyridino 1,2-a pyrimidin-4-one compounds as anticancer agents
US7855295B2 (en) Tetrahydrocarboline compounds as anticancer agents
JP2007512368A5 (cg-RX-API-DMAC7.html)
JP2007500237A5 (cg-RX-API-DMAC7.html)
ES2318478T3 (es) Inhibidores de quinesina mitotica.
CN111423432B (zh) (s)-4/5-苯基-2-(吡咯烷-2-基)噻唑类trpv1拮抗剂及其制备和应用
MXPA06005844A (en) Quinazolinone compounds as anticancer agents

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20051129

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20090508

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20110419

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20110728

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20110419

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I